Gilead Sciences, Inc. (GILD) Bets on Hepatitis C Data to Justify Pharmasset, Inc. (VRUS)'s $10.8 Billion Deal
4/12/2012 8:05:18 AM
More...
|
Gilead Sciences Ltd. (GILD) Completes Acquisition of Pharmasset, Inc. (VRUS)
1/18/2012 5:58:07 AM
More...
|
Gilead Sciences, Inc. (GILD) Completes Tender Offer for All Outstanding Shares of Pharmasset, Inc. (VRUS)
1/12/2012 6:28:32 AM
More...
|
Pharmasset, Inc. (VRUS) to Change Design of Hepatitis C Treatment Study, Says Trial Change Won't Affect Gilead Sciences, Inc. (GILD) Takeover
12/16/2011 8:11:27 AM
More...
|
Gilead Sciences, Inc. (GILD) to Acquire Pharmasset, Inc. (VRUS) for $11 Billion
11/21/2011 7:16:28 AM
More...
|
Pharmasset, Inc. (VRUS) Reports Fiscal Year End 2011 Financial Results
11/15/2011 6:11:51 AM
More...
|
Pharmasset, Inc. (VRUS) to Present at the Lazard Capital Markets Healthcare Conference
11/14/2011 12:24:59 PM
More...
|
Pharmasset, Inc. (VRUS) Rises After Hepatitis-C Drug Shows 100% Cure Rate in Trial
11/7/2011 8:35:53 AM
More...
|
Pharmasset, Inc. (VRUS) to Webcast an Investor Event from the AASLD Meeting
11/4/2011 11:50:17 AM
More...
|
Pharmasset, Inc. (VRUS) Release: New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1
11/4/2011 11:15:32 AM
More...
|
|